Our aim is to determine if automated insulin delivery (AID) systems provide good value compared with standard insulin delivery. We will support the external validation of a computer simulation model (Swedish National Diabetes Register T1D model) which will then be used to estimate the long-term cost-effectiveness (from the US healthcare system and payer perspective) of AID systems versus standard therapy among T1D patients. This is a collaboration among DOR, University of Michigan, Jaeb Center for Health Research, and University of Oxford.
Economic analysis of automated insulin delivery (AID) systems
Investigator: Karter, Andrew
Funder: The Leona M. and Harry B. Helmsley Charitable Trust
